Reaction

Varicella reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,368 reports · 48 co-occurring drugs

As of the last recalculation, Varicella appears in 2,368 FAERS reports alongside 48 co-occurring drug terms. The strongest observed disproportionality signal is ALEMTUZUMAB (PRR 15.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Alemtuzumab	33	15.2	15.2
Anakinra	27	14.5	14.5
Anti-Thymocyte Globulin (Rabbit)	13	14.2	14.3
Basiliximab	17	12.8	12.8
Sirolimus	19	12.5	12.5
Pegaspargase	16	11.6	11.6
Canakinumab	14	11.4	11.4
Atovaquone	10	11.0	11.0
Mycophenolate Mofetil	153	10.5	10.5
Mycophenolate Mofetil Hydrochloride	153	10.5	10.5
Palivizumab	18	10.4	10.4
Fludarabine Phosphate	44	10.0	10.0
Daratumumab	40	8.9	8.9
Azathioprine	84	8.7	8.7
Tacrolimus Extended-Release Capsules	114	8.4	8.4
Tacrolimus Ointment 0.1%	113	8.3	8.3
Tacrolimus	135	8.0	8.0
Obinutuzumab	14	7.5	7.5
Sodium Bicarbonate	19	7.2	7.2
Sodium Bicarbonate Injection,	19	7.2	7.2
Valganciclovir	15	7.0	7.0
Valganciclovir Hydrochloride	15	7.0	7.0
Infliximab	163	7.0	7.0
Ocrelizumab	42	6.0	6.0
Acyclovir	68	5.4	5.4
Thalidomide	20	4.8	4.8
Cyclophosphamide Injection, Solution	93	4.8	4.8
Cyclophosphamide	93	4.8	4.8
Cyclophosphamide For Injection	93	4.8	4.8
Eculizumab	28	4.6	4.6
Bendamustine Hcl	8	4.5	4.5
Busulfan	8	4.5	4.5
Bortezomib	44	4.4	4.4
Golimumab	42	4.4	4.4
Vincristine Sulfate	14	4.2	4.2
Ado-Trastuzumab Emtansine	4	4.2	4.2
Brentuximab Vedotin	4	3.4	3.4
Ivacaftor	3	3.3	3.3
Ustekinumab	36	3.1	3.1
Voclosporin	3	3.0	3.0
Siponimod	3	3.0	3.0
Cannabidiol	7	2.6	2.6
Fam-Trastuzumab Deruxtecan-Nxki	3	2.6	2.6
Ixazomib	7	2.1	2.1
Emicizumab	3	2.1	2.1
Somatropin	14	1.7	1.7
Ixekizumab	7	1.7	1.7
Pomalidomide	15	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.